<code id='E7246C98CD'></code><style id='E7246C98CD'></style>
    • <acronym id='E7246C98CD'></acronym>
      <center id='E7246C98CD'><center id='E7246C98CD'><tfoot id='E7246C98CD'></tfoot></center><abbr id='E7246C98CD'><dir id='E7246C98CD'><tfoot id='E7246C98CD'></tfoot><noframes id='E7246C98CD'>

    • <optgroup id='E7246C98CD'><strike id='E7246C98CD'><sup id='E7246C98CD'></sup></strike><code id='E7246C98CD'></code></optgroup>
        1. <b id='E7246C98CD'><label id='E7246C98CD'><select id='E7246C98CD'><dt id='E7246C98CD'><span id='E7246C98CD'></span></dt></select></label></b><u id='E7246C98CD'></u>
          <i id='E7246C98CD'><strike id='E7246C98CD'><tt id='E7246C98CD'><pre id='E7246C98CD'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:5732
          Adam's take main illustration
          Molly Ferguson/STAT

          Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

          People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

          advertisement

          The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          After decades in use, heart stents finally beat placebo
          After decades in use, heart stents finally beat placebo

          AdobePHILADELPHIA—Anewstudy,andthebolddoctorwholedit,couldresultinbigquestionsabouthowresearchersstu

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          5 important ways Henrietta Lacks changed medical science

          HyacinthEmpinado/STATHenriettaLacks’scellshavelongbeenfamiliartoscientists—butitwastheethicalcontrov